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Abstract A heterotrimeric member of the AMP-activated
protein kinase (AMPK) isoenzyme family was purified from
rat skeletal muscle by immunoaffinity chromatography, consist-
ing of an K2 catalytic and two non-catalytic subunits, L2 and Q1.
The AMPK L2 cDNA (271 amino acids (aa), molecular weight
(MW) = 30 307, pI 6.3) was cloned from skeletal muscle and
found to share an overall identity of 70% with L1 (270 aa,
MW = 30 475, pI 6.0). In the liver AMPK L1 subunit, Ser-182 is
constitutively phosphorylated whereas in skeletal muscle L2
isoform, we find that Ser-182 is only partially phosphorylated. In
addition, the autophosphorylation sites Ser-24, Ser-25 found in
the L1 are replaced by Ala-Glu in the L2 isoform. L2 contains
seven more Ser and one less Thr residues than L1, raising the
possibility of differential post-translational regulation. Immuno-
blot analysis further revealed that soleus muscle (slow twitch)
contains exclusively L1 associated with K2, whereas extensor
digitorum longus muscle K2 (EDL, fast twitch) associates with
L2 as well as L1. Sequence analysis revealed that glycogen
synthase, a known AMPK substrate, co-immunoprecipitated
with the AMPK K2L2Q1 complex.
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1. Introduction
The AMP-activated protein kinase (AMPK) consists of a
catalytic K subunit (550 amino acids (aa)) and non-catalytic L
(270 aa) and Q (323 aa) subunits and multiple isoforms exist
for each subunit [1^3]. Both non-catalytic L and Q subunits are
required for optimal activity of the K catalytic subunit [4].
Several isomers of the AMPK have been identi¢ed whereby
the various subunit isoforms can be found in di¡erent combi-
nations. We will use the nomenclature AMPK K1L1Q1 to de-
scribe an AMPK containing the K1 catalytic subunit together
with L1 and Q1 non-catalytic subunits [5]. AMPK was initially
recognised as a kinase that phosphorylated and inactivated
acetyl-CoA carboxylase and HMG-CoA reductase, key regu-
latory enzymes in the control of fatty acid and cholesterol
synthesis, respectively [6]. Recently, it has become clear that
AMPK plays a more extensive and dynamic role in modulat-
ing metabolism in response to energy demand and nutrient
availability, mediating exercise-induced glucose uptake in
muscle and activation of endothelial NO synthase [5,7].
AMPK is activated by elevation of intracellular AMP caused
by metabolic stress that can be induced by high-energy de-
mand, heat shock or toxins [5]. The activation of AMPK by
AMP results from three contributing mechanisms. These are
direct allosteric activation of the enzyme, activation of an
upstream kinase kinase [8] and inhibition of AMPK dephos-
phorylation [9] that is thought to provide an exquisitely sen-
sitive mechanism for monitoring the cellular energy status
[10].
Previously, we reported the identi¢cation of two catalytic
isoforms (K1 and K2) of the AMPK in rat liver [11]. Both
isoforms could be stimulated by AMP and contained non-
catalytic L and Q subunits. The K1 and K2 catalytic isoforms
of the AMPK are 90% identical in the catalytic core region,
but only 60% identical in their COOH-terminal tails. In addi-
tion, sequence analysis of L and Q non-catalytic subunits has
revealed the presence of additional genes for each subunit
within the human genome [12]. Since the AMPK consists of
a family of isoenzymes, it is important to establish which L
and Q subunit isoforms are bound to each catalytic isoform
and whether the isoenzymes are di¡erentially expressed in
di¡erent tissues and cell types. Rat and porcine liver contain
the AMPK isoenzymes K1L1Q1 and K2L1Q1 [3,13,14]. It was
initially reported that skeletal muscle AMPK was not associ-
ated with L or Q non-catalytic subunits [15] but we noted the
presence of a L2 isoform form in the EST database [14].
Thornton et al. [16] have now reported that the human L2
isoform interacts with human AMPK K2 subunit using the
yeast two hybrid technique. They claimed that L2 was the
dominant isoform expressed in skeletal muscle. In the present
study, we show that skeletal muscle AMPK K2 is associated
with Q1 and either L2 or L1 depending on the muscle type.
2. Materials and methods
2.1. AMPK K2 puri¢cation
Rattus norvegicus skeletal muscle (hind leg, approximately 500 g)
was homogenised in 2 l bu¡er (50 mM Tris-HCl pH 8.5, 250 mM
sucrose, 50 mM NaF, 5 mM Na-pyrophosphate, 1 mM EGTA, 1 mM
EDTA, 1 mM DTT, 1 mM PMSF and 1 mM benzamidine) using an
Ultra-Turrax (IKA-Labortechnik, Bremen, Germany). The homoge-
nate was centrifuged at 5000Ug for 30 min and the supernatant was
fractionated by 1^7% polyethylene glycol (PEG 6000) fractionation.
The ¢nal pellet was resuspended in 1 l of 50 mM Tris-HCl pH 7.5,
50 mM NaF, 5 mM Na-pyrophosphate, 1 mM EGTA, 1 mM EDTA,
1 mM DTT and 5% glycerol (bu¡er A) before batch application to 1 l
of DE52 Sepharose (Whatman, Maidstone, UK). The resin was eluted
with bu¡er A containing 0.5 M NaCl and the volume reduced by 10%
PEG 6000 precipitation. The pellet was suspended in 30 ml bu¡er A
and passed through an ADR1 (222^234)P229-peptide a⁄nity column
[17] to deplete contaminating AMPK K1. The AMPK K2 present in
the £ow-through was a⁄nity-puri¢ed by immunoprecipitation with
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equal amounts (250 Wg) of anti-AMPK K2 (352^366) and K2 (490^
516) polyclonal antibodies [11] coupled to 250 Wl (slurry) of Tosyl-
activated Dynabeads (Dynal, Oslo, Norway) according to the manu-
facturer’s instructions. The magnetic beads were collected, washed
twice with 1 ml phosphate-bu¡ered saline, 3U1 ml 50 mM Tris pH
7.4, 1 mM EDTA, 0.5 M NaCl and 1% Triton X-100, and 2U1 ml
with the same bu¡er containing 2% Triton X-100. Proteins were
eluted by boiling in sodium dodecyl sulfate (SDS) sample bu¡er con-
taining 10 mM DTT and subjected to 12% SDS-polyacrylamide gel
electrophoresis (PAGE).
2.2. Antibody production
Polyclonal antibodies against AMPK peptides were prepared as
described [11]. AMPK K1 antibodies were raised against the pep-
tide CARHTLDELNPQKSKHQG-COOH (373^390)C373. AMPK
L1 antibodies were raised against the peptide CSSPPGPYHQE-
PYISKPE-NH2 (181^197)C181 and AMPK L2 antibodies against
the peptide CGPGKEHKIMVGSTDDPSV-NH2 (26^44)C26 while
AMPK Q1 antibodies were raised against the peptide CQALVLTG-
GEKKP-COOH (319^331)C319.
2.3. Peptide sequencing
Proteins separated by SDS-PAGE were sequenced using a modi¢ed
in situ proteolysis technique as described [14] using a Hewlett Packard
G1000A Protein Sequencer and a PerSeptive Biosystems Voyager DE
MALDI-TOF mass spectrometer.
2.4. Cloning of AMPK L2 cDNA
Total RNA was extracted from 5 g rat hind leg skeletal muscle
using Total RNA Isolation Reagent (Advanced Biotechnologies, Sur-
rey, UK) according to the manufacturer’s instructions. One Wg of
RNA from this preparation was used to generate cDNA using the
primer AATTCGCGGCCGC(dT)15, containing a NotI restriction
site, with Superscript II reverse transcriptase (Gibco) followed by
RNAse H (Gibco) digestion. An initial 473 bp fragment was ampli¢ed
by polymerase chain reaction (PCR) using degenerate primers based
on the sequenced peptides MVGSTDDP and GQEMYVF (sense:
CTGCAGGAATTCATGGTGGGGAGCACNGAYGAYCC con-
taining an EcoRI site 5P, antisense: ATCGATAAGCTTRAANACR-
TACATYTCYTGNCC including a 5P HindIII site. The product was
cloned into the EcoRI and HindIII sites of pBluescript SK(3) (Stra-
tagene) for sequence con¢rmation. To obtain the 5P coding region,
cDNA was synthesised using the primer GATATCGAATTC-
GACTCTTAATCAGAGGGATCTTGG, based on the 473 bp frag-
ment. A 176 bp fragment was then PCR-ampli¢ed using a 5P-RACE
strategy (Gibco) between the anchor primer (Gibco) and the nested
reverse primer, GATATCGAATTCAGGGAGCTTGGAGTCCGG-
CAG. PCR conditions were 1 min at 94‡C, 1 min at 55‡C and
2 min at 72‡C. The PCR product was ligated into pCR-SCRIPT for
cloning and sequencing. 3P Coding and untranslated residues were
obtained using a nested PCR approach. The cDNA synthesis and
reverse PCR primer was AATTAACCCTCACTAAAGGG(dT)15
based on the T3 promoter, while forward primers were GCTGCA-
GAATTCGGAAAGCTCTGAGACATCATGTCG and GACATC-
GAATTCATGTCGAGACCTGTCCAGCTC for initial and nested
PCRs, respectively. Both rounds of PCR were for 35 cycles of 94‡C
for 1 min, 50‡C for 1 min and 72‡C for 5 min. The 1225 bp fragment
was ligated directly into SmaI-digested, alkaline phosphatase-treated
pBluescript SK(3) for cloning and sequencing as above. Sequences of
both strands of plasmids were determined using an ABI model 305
automated sequencer and ABI Prism sequencing kits as recommended
by the manufacturer. The cDNA sequence was submitted to GenBank
and has been assigned the GenBank accession number AF182717.
2.5. Immunoblotting
Anti-AMPK K2 (490^516) antibody Dynabeads (see above) were
incubated with the partially puri¢ed AMPK K2 overnight with gentle
mixing at 4‡C. The magnetic beads were collected, washed with 2U1
ml phosphate-bu¡ered saline, 3U1 ml 50 mM Tris pH 7.4, 1 mM
EDTA, 0.5 M NaCl and 1% Triton X-100 and 2U1 ml with the
same bu¡er containing 2% Triton X-100. The magnetic beads were
boiled in SDS sample bu¡er containing 10 mM DTT, subjected to
12% SDS-PAGE and transferred to PVDF. The immunoblot was
blocked in 5% milk powder, 0.1% Tween 20, in phosphate-bu¡ered
saline and incubated with the a⁄nity-puri¢ed [12] (10 Wg/ml) AMPK
antibodies described in Fig. 2. Primary antibody was detected using
goat anti-rabbit antibody conjugated to horseradish peroxidase
(Dako) and the Amersham ECL detection system. All of the primary
antibodies were prepared and a⁄nity-puri¢ed as described previously
[11]. The positive control (+) used in these blots was a partially pu-
ri¢ed fraction from rat liver containing AMPK isoforms K1L1Q1 and
K2L1Q1 [17]. In addition, an antibody control consisting of rabbit IgG
coupled at the same concentration as the K2 antibody to Tosyl-acti-
vated Dynabeads was used to verify K2 speci¢city.
2.6. Rat muscle immunoprecipitation and immunoblot
Male Sprague Dawley rats were anaesthetised with sodium pento-
barbitone. The extensor digitorum longus (EDL) and soleus muscles
were excised and snap frozen in liquid nitrogen. The muscles were
homogenised in bu¡er (50 mM Tris-HCl, pH 7.5, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 50 mM NaF, 5 mM Na-pyrophosphate,
10% glycerol, 1% Triton X-100, 10 Wg/ml trypsin inhibitor, 2 Wg/ml
aprotinin, 1 mM benzamidine and 1 mM PMSF). The homogenates
were incubated with AMPK K1 (373^390) or AMPK K2 (490^516)
antibody-bound protein A beads for 2 h at 4‡C. The immunocomplex
was washed with PBS and boiled in SDS sample bu¡er. The samples
were separated by 10% SDS-PAGE, transferred to PVDF membranes
and immunoblotted with antibodies speci¢c for L1 and L2.
3. Results
The AMPK isoenzyme containing the K2 catalytic subunit
was partially puri¢ed from rat skeletal muscle and isolated by
immunoa⁄nity chromatography using an antibody against
the AMPK K2 catalytic subunit (Fig. 1). The identity of the
AMPK K2 catalytic subunit (63 kDa) was veri¢ed by peptide
sequence analysis. For the predicted K2 band, 24 out of 34
masses were initially identi¢ed as K2 peptides based on ex-
pected tryptic digest masses. Three of the identi¢ed peptides
were also con¢rmed by peptide sequencing, corresponding to
sequences 270^299, 382^393 and 489^499, respectively (data
not shown). The remaining masses could not be con¢dently
matched to the K2 sequence and appear to be minor contam-
inants co-eluting with K2 peptides. Thus, 45% of the K2 cata-
lytic subunit sequence was detected including seven peptides
derived from the catalytic core and 10 peptides from the C-
terminal domain. Immunoblot analysis also con¢rmed that
the K2 catalytic subunit and not the K1 catalytic subunit im-
munoprecipitated with the K2 speci¢c antibodies (Fig. 2).
In order to identify the proteins associated with the AMPK
K2 catalytic subunit, the co-immunoprecipitated bands were
also identi¢ed by a combination of mass spectrometry and
Edman sequencing of tryptic peptides generated from ‘in-
gel’ digests of individual bands (Fig. 1). Tryptic digestion of
the 34 kDa band resulted in 13 peptides related to a human L2
EST consensus sequence previously reported [14] and ac-
counted for 51% of the expected 271 residues of the L2 protein
sequence (Fig. 3A). Two additional peptides sequenced corre-
sponded to peptides from porcine trypsin and the IgG heavy
chain. Immunoblot analysis of the AMPK K2 skeletal muscle
immunoprecipitate also con¢rmed that it contained a 34 kDa
band corresponding to the L2 subunit and negligible amounts
of the L1 subunit (Fig. 2), consistent with the peptide sequenc-
ing data. In L1, the peptide containing Ser-182 is stoichiomet-
rically phosphorylated [18]. In contrast, L2 was substantially
dephosphorylated at this site and the dephosphorylated tryp-
tic peptide, DLSSSPPGPYGQEMYVFR, identi¢ed by mass
and Edman sequencing (5.2 pmol, 100% repetitive yield). The
only phosphorylated form of the peptide detected was
DLSSSPPGPYGQEMY, generated by a chymotryptic-like
cleavage (2.8 pmol, 98% repetitive yield).
Tryptic peptide sequences derived from the 38 kDa protein
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(Fig. 1) were identical to the Q1 isoform (data not shown) and
accounted for 43% of the sequence. In addition, Q1 speci¢c
antibodies identi¢ed a 38 kDa band as Q1 in an AMPK K2
immunoprecipitate (Fig. 2). These results demonstrate that the
skeletal muscle AMPK K2 catalytic subunit associates with
the L2 and Q1 non-catalytic subunits. This contrasts with liver
where the AMPK K2 catalytic subunit associates with the L1
and Q1 non-catalytic subunits [11].
The full length L2 sequence was obtained by a combination
of reverse transcription (RT-) PCR and 5P and 3P-RACE. An
initial 473 bp PCR product (see Section 2) was used to design
primers for both 5P-RACE and 3P-RACE strategies to obtain
the complete coding sequence of L2. The 5P-RACE product
was 176 bp and the 3P-RACE product was 1225 bp in length.
The sequences of both fragments overlapped with the RT-
PCR core fragment and were identical beyond the primer
sequences in these overlaps. This demonstrates that all three
fragments were derived from the same mRNA species. Com-
bined, these clones covered an open reading frame, encoding a
protein of 271 aa with a predicted myristoylation sequence at
the N-terminus (Fig. 3A). Comparison with the L1 protein
revealed 70% overall identity with only 43% aa identity in
the N-terminal 72 residues of the protein while the remainder
is 82% identical (Fig. 3B). The N-terminal 33 residues of the
cDNA-predicted sequence would be expected to yield short
tryptic peptides that would elute in the £ow-through of the
reversed phase column (Fig. 3A). The predicted mass of the
myristoylated L2 is 30 306 compared to 34 kDa estimated by
SDS-PAGE. When isolated from liver, the L1 subunit is
present as the myristoylated mono-, di- and tri-phosphoryl-
ated forms with masses of 30 552, 30 365 and 30 722, respec-
tively [18], and migrates on SDS-PAGE at approximately 40
kDa. Therefore, the slower than expected mobility of L1 in
SDS-PAGE may be due to aberrant electrophoretic behaviour
that is less pronounced for L2.
Immunopuri¢ed skeletal muscle AMPK K2L2Q1 also con-
tained proteins in the 80^97 kDa range (Fig. 1). Tryptic pep-
tide sequencing revealed that they corresponded to glycogen
synthase (residues 40^50, 130^145, 211^230, 322^330 and 615^
634) and glycogen phosphorylase (residues 193^206 and 492^
307), respectively. Previously, glycogen synthase was reported
to be a substrate of the AMPK [19]. Hence, the association of
glycogen synthase observed here with the AMPK is consistent
with it acting as a substrate in vivo. Glycogen phosphorylase
associates with glycogen synthase but is not a substrate for the
AMPK (Beyer et al., personal communication).
To test if the AMPK subunit composition di¡ered accord-
ing to the muscle type, fast and slow twitch muscle samples
from normal rats were homogenised and immunoprecipitated
with either AMPK K1 or K2 speci¢c antibodies and immuno-
blotted for the presence of L1 or L2 speci¢c isoforms. Fast
twitch EDL muscle (E) was found to contain both isoforms
L1 and L2 but slow twitch soleus muscle (S) only contained
the L1 isoform (Fig. 4). The L2 subunit was only found asso-
ciated with the AMPK K2 catalytic subunit and not with K1.
4. Discussion
The di¡erential localisation of the two AMPK isoforms and
activation provides an important basis for understanding their
physiological roles in metabolic sensing in di¡erent muscle
types. Previously, skeletal muscle exercise was reported to
elevate AMPK activity [20] and more recently, electrical stim-
Fig. 2. Immunoblot analysis of skeletal muscle AMPK K2 immuno-
precipitate. AMPK K2 was puri¢ed and blotted as described in Sec-
tion 2. Lane A contains skeletal muscle AMPK K2 immunoprecipi-
tates, lane B contains IgG control immunoprecipitates and lane C a
partially pure AMPK preparation from rat liver that contains both
K1L1Q1 and K2L1Q1 isoenzymes. Antibodies used for blotting are
shown and the details of each can be found in Section 2. Arrows in-
dicate subunits and IgG heavy chain.
Fig. 1. Immunopuri¢cation of rat liver AMPK K2. AMPK K2 was
puri¢ed as described in Section 2. Shown is an SDS-polyacrylamide
gel (12%) containing the AMPK K2 catalytic subunit together with
the AMPK non-catalytic subunits, L and Q. Antibody heavy chain,
glycogen phosphorylase and glycogen synthase are also shown. Mo-
lecular weight standards are shown in kDa.
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ulation of skeletal muscle was found to cause a rapid rise in
activity of the AMPK K2 isoform [21]. Activation of the
AMPK in skeletal muscle serves to stimulate fatty acid oxi-
dation via phosphorylation of acetyl-CoA carboxylase [20]
and increase glucose uptake [22] by translocation of GLUT4
to the plasma membrane.
The AMPK K2 catalytic subunit associates with both L1
and L2 in fast twitch muscle and L1 alone in slow twitch
muscle using muscle lysates. Any L1 that may have been as-
sociated with K2 was essentially lost during the partial puri¢-
cation of the K2L2Q1 isoenzyme, though trace amounts can be
observed in the immunoblot shown in Fig. 2.
Previously, we found that L1 isolated from rat liver was
present in mono-, di- and tri-phospho forms. The phospho-
rylated residues detected were Ser-24, Ser-25 (either but not
both), Ser-108 and Ser-182 [18]. In the case of L2, Ser-24-Ser-
Fig. 3. A: AMPK L2 cDNA sequence. The sequence of the AMPK L2 cDNA and the deduced aa sequence are shown. Peptides that were se-
quenced from the 34 kDa band (Fig. 1) are underlined. The Ser-182 site that was found both phosphorylated and dephosphorylated is boxed.
B: Comparison of AMPK L1 and L2 aa sequences. The sequences shown, human L1, accession number Y12556; rat L1, accession number
P80386; Caenorhabditis elegans L1, accession number CAB04480; human L2, accession number AJ224538.1; rat L2, GenBank accession number
AF182717 and C. elegans L2, accession number Y47D3A.q (found at http://wormserver.sanger.as.uk/cgi-bin/ace/sequence) were aligned with
Clustalw and formatted [23]. Conserved aa are highlighted.
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Fig. 3 (continued)
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25 is replaced by Ala-Glu. The Ser-182 site in L2 is present as
both the phosphorylated and dephosphorylated peptide based
on the mass and sequence of the tryptic peptide,
DLSSSPPGPYGQEMY. This suggests that in L2, the Ser-
182-phosphate site is turning over whereas in the L1 isoform
present in liver, it is stoichiometrically phosphorylated. Over-
all, L2 has 28 Ser residues compared to 21 for L1 and 14
versus 15 Thr residues, respectively (Fig. 3B). Comparing L2
and L1, there are 16 sites where Ser/Thr residues are substi-
tuted with non-hydroxyl containing aa, suggesting the poten-
tial for considerable diversity in the phosphorylation patterns
of these proteins.
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Fig. 4. Distribution of the AMPK L subunits in fast and slow
twitch skeletal muscle. Rat EDL (E) and soleus (S) muscles were
homogenised, immunoprecipitated (using AMPK K1 and K2 speci¢c
antibodies) and immunoblotted for both AMPK L1 and AMPK L2
as described in Section 2. IgG is indicated.
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